In the Era of Immune Checkpoint Inhibitor Therapy, Can We Safely Expand to Patients with Immunodeficiency?

In the Era of Immune Checkpoint Inhibitor Therapy, Can We Safely Expand to Patients with Immunodeficiency?

Bibliographic Details
Main Authors:	Mehmet Asim Bilen, Razelle Kurzrock
Format:	Article
Language:	English
Published:	Innovative Healthcare Institute 2019-10-01
Series:	Journal of Immunotherapy and Precision Oncology
Online Access:	https://jipo.org/doi/pdf/10.4103/JIPO.JIPO_20_19

Similar Items

Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials
by: Tony Zibo Zhuang, et al.
Published: (2022-06-01)

Immune Checkpoint Inhibitors in Cancer Therapy—How Can We Improve Clinical Benefits?
by: Constantin N. Baxevanis
Published: (2023-01-01)

Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches
by: Alireza Tojjari, et al.
Published: (2023-11-01)

166 High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with outcome on immune checkpoint inhibitors
by: Razelle Kurzrock, et al.
Published: (2023-11-01)

Repurposing Interleukin-6 Inhibitors to Combat COVID-19
by: Shumei Kato, et al.
Published: (2020-05-01)

PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
by: Yuan Gao, et al.
Published: (2022-10-01)

Immune-checkpoint inhibitors for glioblastoma: what have we learned?
by: Antonio Omuro
Published: (2022-08-01)

miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors
by: Florian Huemer, et al.
Published: (2021-01-01)

Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
by: Jingyu Jiang, et al.
Published: (2023-02-01)

Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals
by: Daniel D. Shapiro, et al.
Published: (2023-04-01)

Oropharyngeal Squamous Cell Carcinoma Treatment in the Era of Immune Checkpoint Inhibitors
by: Peter L. Stern, et al.
Published: (2021-06-01)

The Extended Surgical Concepts for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors
by: Hsu HM, et al.
Published: (2023-10-01)

Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression
by: Chao Chen, et al.
Published: (2023-09-01)

Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy
by: Julie M. Collins, et al.
Published: (2018-08-01)

The Abscopal Effect in the Era of Checkpoint Inhibitors
by: Ondřej Kodet, et al.
Published: (2021-07-01)

Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?
by: Choong-kun Lee, et al.
Published: (2022-06-01)

Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients
by: Abdullah Al-Danakh, et al.
Published: (2024-03-01)

Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives
by: Brigida Anna Maiorano, et al.
Published: (2021-09-01)

Immune Checkpoint Inhibitors in Cancer Therapy
by: Yavar Shiravand, et al.
Published: (2022-04-01)

Immune checkpoint inhibitors in the treatment of oesophageal squamous cell carcinoma: where are we and where are we going?
by: Ning Chen, et al.
Published: (2023-08-01)

The role of neurologists in the era of cancer immunotherapy: Focus on CAR T-cell therapy and immune checkpoint inhibitors
by: Umberto Pensato, et al.
Published: (2022-07-01)

Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?
by: Chiara L. Blomen, et al.
Published: (2021-12-01)

Cancer and Immune Checkpoint Inhibitor Treatment in the Era of SARS-CoV-2 Infection
by: Thilo Gambichler, et al.
Published: (2020-11-01)

Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era
by: Chiara Burgaletto, et al.
Published: (2021-04-01)

Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?
by: David Repáraz, et al.
Published: (2022-02-01)

Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions
by: Yi-xuan Yu, et al.
Published: (2023-05-01)

Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors
by: Curtis A. Clark, et al.
Published: (2023-01-01)

Immune Checkpoint Inhibitors and Opioids in Patients with Solid Tumours: Is Their Association Safe? A Systematic Literature Review
by: Massimiliano Cani, et al.
Published: (2022-12-01)

Advanced Research on Immune Checkpoint Inhibitor Therapy
by: Hisao Imai, et al.
Published: (2022-09-01)

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
by: Juwon Lee, et al.
Published: (2021-07-01)

The Role of Immune Checkpoint Inhibitors in Cancer Therapy
by: Ahmed M. Basudan
Published: (2022-12-01)

Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy
by: John M. Rieth, et al.
Published: (2021-03-01)

Circulating and Tumor-Associated Neutrophils in the Era of Immune Checkpoint Inhibitors: Dynamics, Phenotypes, Metabolism, and Functions
by: Lara Gibellini, et al.
Published: (2023-06-01)

The Role of Radiomics in the Era of Immune Checkpoint Inhibitors: A New Protagonist in the Jungle of Response Criteria
by: Angelo Castello, et al.
Published: (2022-03-01)

Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
by: Soumaya Karaki, et al.
Published: (2016-11-01)

New Frontiers about the Role of Human Microbiota in Immunotherapy: The Immune Checkpoint Inhibitors and CAR T-Cell Therapy Era
by: Vanessa Innao, et al.
Published: (2020-11-01)

Immune Checkpoint Inhibitors and Lupus Erythematosus
by: Hans Vitzthum von Eckstaedt, et al.
Published: (2024-02-01)

Editorial: Nephrotoxicity of immune checkpoint inhibitors
by: Tess Van Meerhaeghe, et al.
Published: (2024-01-01)

Cardiovascular complications of immune checkpoint inhibitors
by: A. A. Kulievа, et al.
Published: (2020-04-01)

Cardiotoxicity Associated with Immune Checkpoint Inhibitors
by: Shintaro Minegishi, et al.
Published: (2023-11-01)